Breaking News Instant updates and real-time market news.

PTI

Proteostasis

$2.84

-0.23 (-7.49%)

16:24
07/31/17
07/31
16:24
07/31/17
16:24

Proteostasis announces progression CF study to longer duration studies

Proteostasis Therapeutics announced updates across the company's later stage development programs in CF, including PTI-428, a cystic fibrosis transmembrane conductance regulator, CFTR, amplifier, PTI-801, a new generation CFTR corrector, and PTI-808, a CFTR potentiator. Proteostasis announced that it has completed dosing of 19 patients as part of the ongoing Phase 1/2 study designed to evaluate the safety and pharmacokinetics of PTI-428, the company's CFTR amplifier. PTI-428 was administered together with background Orkambi or as the only CFTR modulator therapy in CF subjects over a 14-day period. The trial met its primary safety and pharmacokinetic endpoints, confirming PTI-428's safety, tolerability and lack of clinically meaningful drug-drug interaction with ivacaftor and lumacaftor. "Preliminary data suggests that PTI-428 continues to demonstrate a favorable safety and pharmacokinetic profile, which has enabled the initiation of Phase 2, enrolling CF subjects on background Orkambi taking PTI-428 or placebo for 28 days," said Meenu Chhabra, President and CEO of Proteostasis Therapeutics. "We continue to make meaningful progress with all three components of our proprietary triple combination: with the support of US and EU patient advocacy groups for the PTI-801 protocol, we are eligible to begin screening and enrolling CF subjects on background Orkambi and 40 clinical sites in the US, Canada and EU have been identified or are in process of activation; enrollment continues in our 28-day study of PTI-428 across 14 active clinical sites in the US, with activation of another 23 sites in both the US and EU in process; and we have initiated a Phase 1 study of PTI-808 in healthy volunteers." In the Phase 1 portion of the PTI-428 study, 11 subjects in the Orkambi cohort and eight in the PTI-428 monotherapy cohort were enrolled, with each group enrolling 2 placebo subjects. All adverse events (were mild or moderate and none occurred in more than one subject. There were no hematology-related adverse events and no serious adverse events reported. Safety endpoints evaluated included lung function as measured by forced expiratory volume in one second, although the study was not designed to show a statistically significant difference. In the subjects who received PTI-428 in addition to their background Orkambi, there was no significant improvement of FEV1 compared to placebo, although there was a numerical increase in FEV1 at day 7. Measurements of sweat chloride and mRNA in nasal mucosa were used as exploratory biomarkers but the changes were not significant nor correlated with lung function changes. Ms. Chhabra added, "While confirming the safety of PTI-428, the phase 1 portion of this study was not expected to demonstrate efficacy over a 7-day dosing period, as PTI-428, as a CFTR amplifier, is designed to deliver substrate to correctors and was investigated in combination with Orkambi, whose signal of efficacy required a 28-day study. As a result, we look forward to generating data in our 28-day proof-of-concept study to begin understanding the activity profile of PTI-428." Proteostasis is enrolling patients in the Phase 2 safety and efficacy portion of the study, which explores PTI-428 dosed over a 28-day period, and preliminary data is expected in Q4 2017.

PTI Proteostasis
$2.84

-0.23 (-7.49%)

11/01/16
WBLR
11/01/16
DOWNGRADE
Target $81
WBLR
Market Perform
William Blair downgrades Vertex with competition looming
William Blair analyst Y. Katherine Xu downgraded Vertex Pharmaceuticals (VRTX) to Market Perform from Outperform after attending the North American Cystic Fibrosis Conference. Looming competition "has become more and more real," Xu tells investors in a research note. The triple combo in vitro data from Vertex, AbbVie (ABBV)/Galapagos (GLPG) and Proteostasis (PTI) appear comparable, Xu contends. The analyst expects "deteriorating pricing" for the Vertex's Cystic Fibrosis franchise starting in 2022 due to competition. She lowered her price target for the shares to $81 from $105. Vertex closed yesterday at $78.86.
08/12/16
LEER
08/12/16
NO CHANGE
Target $20
LEER
Outperform
Proteostasis price target raised to $20 from $15 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Proteostasis to $20 from $15 after the company reported promising data from a Phase 1 study of its PTI-248, which is being developed as an add-on to amplify the effect of currently approved therapies for cystic fibrosis. Leerink has an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BABA

Alibaba

$159.50

1.75 (1.11%)

, WMT

Wal-Mart

$80.98

0.21 (0.26%)

20:25
08/16/17
08/16
20:25
08/16/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BABA

Alibaba

$159.50

1.75 (1.11%)

WMT

Wal-Mart

$80.98

0.21 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 18

    Aug

  • 16

    Nov

  • 20

    Feb

ATU

Actuant

$22.90

-0.2 (-0.87%)

19:22
08/16/17
08/16
19:22
08/16/17
19:22
Hot Stocks
Actuant agrees to divest Viking SeaTech, acquire Mirage Machines »

Actuant Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$46.41

0.9 (1.98%)

19:17
08/16/17
08/16
19:17
08/16/17
19:17
Hot Stocks
Novo Nordisk: SUSTAIN 7 results show superior reduction in HbA1c »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

GOOG

Alphabet

$926.96

4.74 (0.51%)

, GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

18:48
08/16/17
08/16
18:48
08/16/17
18:48
Periodicals
Google acquires AIMatter, TechCrunch reports »

Google has acquired…

GOOG

Alphabet

$926.96

4.74 (0.51%)

GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 18

    Aug

  • 24

    Aug

SRUN

Silver Run

$10.19

0.01 (0.10%)

18:37
08/16/17
08/16
18:37
08/16/17
18:37
Hot Stocks
Silver Run merging with Alta Mesa and Kingfisher Midstream into $3.8B company »

Silver Run Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$85.55

-0.87 (-1.01%)

18:37
08/16/17
08/16
18:37
08/16/17
18:37
Downgrade
Heico rating change at Deutsche Bank »

Heico downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 07

    Sep

GPRK

GeoPark

$8.61

-0.13 (-1.49%)

18:36
08/16/17
08/16
18:36
08/16/17
18:36
Earnings
GeoPark reports Q2 revenue $75.2M, consensus $70.38M »

Reports Q2 consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

MEDP

Medpace

$31.21

-0.16 (-0.51%)

18:14
08/16/17
08/16
18:14
08/16/17
18:14
Hot Stocks
Medpace announces stock repurchase agreement with Cinven »

Medpace Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

TOUR

Tuniu

$7.76

-0.18 (-2.27%)

18:04
08/16/17
08/16
18:04
08/16/17
18:04
Earnings
Tuniu reports Q2 EPS (11c), consensus (26c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

GLDD

Great Lakes Dredge

$3.85

-0.15 (-3.75%)

18:03
08/16/17
08/16
18:03
08/16/17
18:03
Hot Stocks
Great Lakes Dredge CEO acquires 42,610 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISI

Team

$11.10

-0.25 (-2.20%)

18:00
08/16/17
08/16
18:00
08/16/17
18:00
Hot Stocks
Team director Lois Waters purchases 17,500 shares of company stock »

Team director Lois Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:59
08/16/17
08/16
17:59
08/16/17
17:59
Hot Stocks
Breaking Hot Stocks news story on NetApp »

NetApp says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

NTAP

NetApp

$42.41

0.44 (1.05%)

17:58
08/16/17
08/16
17:58
08/16/17
17:58
Hot Stocks
Breaking Hot Stocks news story on NetApp »

NetApp says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

NTAP

NetApp

$42.42

0.44 (1.05%)

17:52
08/16/17
08/16
17:52
08/16/17
17:52
Earnings
NetApp sees low double digit EPS growth for FY18, consensus $3.03 »

Sees FY18 adjusted gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

SFST

Southern First Bancshares

$36.00

0.05 (0.14%)

17:50
08/16/17
08/16
17:50
08/16/17
17:50
Hot Stocks
Southern First Bancshares CFO Michael Dowling sells 5,850 shares »

Southern First Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BXE

Bellatrix Exploration

$2.40

-0.03 (-1.23%)

17:49
08/16/17
08/16
17:49
08/16/17
17:49
Hot Stocks
Bellatrix Exploration regains NYSE minimum price compliance »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$42.41

0.44 (1.05%)

17:48
08/16/17
08/16
17:48
08/16/17
17:48
Hot Stocks
NetApp says headwind for services revenue to decrease in coming quarters »

Comments from Q1 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 06

    Sep

  • 14

    Sep

ACHN

Achillion

$4.88

-0.12 (-2.40%)

17:45
08/16/17
08/16
17:45
08/16/17
17:45
Conference/Events
Achillion management to meet with William Blair »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

BCOR

Blucora

$23.35

0.1 (0.43%)

, BBOX

Black Box

$3.75

-0.25 (-6.25%)

17:35
08/16/17
08/16
17:35
08/16/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Blucora (BCOR),…

BCOR

Blucora

$23.35

0.1 (0.43%)

BBOX

Black Box

$3.75

-0.25 (-6.25%)

BGG

Briggs & Stratton

$24.09

0.29 (1.22%)

LB

L Brands

$39.55

0.5 (1.28%)

VIPS

Vipshop

$11.10

-0.07 (-0.63%)

SPTN

SpartanNash

$25.96

0.07 (0.27%)

SNPS

Synopsys

$79.09

0.86 (1.10%)

CSCO

Cisco

$32.34

0.25 (0.78%)

NTAP

NetApp

$42.41

0.44 (1.05%)

LAKE

Lakeland Industries

$15.65

-0.25 (-1.57%)

GCP

GCP Applied Technologies

$28.75

0.1 (0.35%)

FNGN

Financial Engines

$34.35

-0.1 (-0.29%)

ACHC

Acadia

$51.68

-0.33 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 29

    Aug

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 14

    Sep

  • 30

    Nov

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

, WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

17:26
08/16/17
08/16
17:26
08/16/17
17:26
Upgrade
Andeavor Logistics, Western Refining Logistics rating change at MUFG »

Andeavor Logistics…

ANDX

Andeavor Logistics

$46.94

0.12 (0.26%)

WNRL

Western Refining Logistics

$24.25

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$200.61

1.12 (0.56%)

17:22
08/16/17
08/16
17:22
08/16/17
17:22
Hot Stocks
General Dynamics awarded $115.3M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

BLVD

Boulevard Acquisition

$10.04

-0.01 (-0.10%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Hot Stocks
Breaking Hot Stocks news story on Boulevard Acquisition »

Glazer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$34.85

-0.33 (-0.94%)

17:17
08/16/17
08/16
17:17
08/16/17
17:17
Syndicate
First Mid-Illinois Bancshares files to sell $20M of common stock 'at-the-market' »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

NCOM

National Commerce

$39.55

0.1 (0.25%)

17:16
08/16/17
08/16
17:16
08/16/17
17:16
Hot Stocks
National Commerce, FirstAtlantic Financial sign definitive merger agreement »

National Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMGN

Amgen

$171.39

1.35 (0.79%)

17:13
08/16/17
08/16
17:13
08/16/17
17:13
Hot Stocks
Amgen: NEJM publishes results from Repatha cognitive function trial »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 08

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.